Edition:
India

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

558.65INR
10:05am IST
Change (% chg)

Rs19.05 (+3.53%)
Prev Close
Rs539.60
Open
Rs549.00
Day's High
Rs561.00
Day's Low
Rs545.10
Volume
1,802,962
Avg. Vol
2,742,551
52-wk High
Rs564.00
52-wk Low
Rs295.03

Select another date:

BUZZ-India's Biocon hits near 2-week high on tie-up with Sandoz

** Biocon Ltd rises as much as 3.9 pct at 560.35 rupees, its highest since Jan 8

BRIEF-Biocon Announces Exclusive Global Collaboration With Sandoz On Next-Generation Biosimilars

* ANNOUNCES EXCLUSIVE GLOBAL COLLABORATION WITH SANDOZ ON NEXT-GENERATION BIOSIMILARS'

BRIEF-Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil

* CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS

BRIEF-Biocon Says Has Paid Facility Fee For Its API Facility To U.S. FDA

* CLARIFIES ON NEWS ITEM REGARDING CO'S NAME ON FDA LIST FOR NOT PAYING FACILITY FEE

BRIEF-India's Biocon To Transfer Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India

* INDIA'S BIOCON SAYS TO TRANSFER BIOSIMILAR BUSINESS THROUGH SLUMP SALE AS 'GOING CONCERN' TO BIOCON BIOLOGICS INDIA - EXCHANGES

BUZZ-India's Biocon hits record high on U.S. FDA approval for generic cancer drug Ogivri

** Biocon Ltd jumps as much as 13.8 pct to hit a record high of 509.00 rupees

BUZZ-India's Biocon hits record high; EU regulator OKs marketing applications for generic cancer drugs

** Biocon Ltd jumped as much as 3.6 pct to touch a record high of 447.60 rupees

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

BRIEF-Biocon ‍launches Krabeva in India​

* Launches Krabeva - biosimilar Bevacizumab for treating several types of cancer in India​

BUZZ-India's Biocon jumps on green signal for U.S. export

** Shares of Biocon Ltd surge as much as 6.4 pct, their biggest intraday pct gain since Nov. 17

Select another date: